ATE260104T1 - Hemmung der endprodukte fortgeschrittener glykolisierung - Google Patents

Hemmung der endprodukte fortgeschrittener glykolisierung

Info

Publication number
ATE260104T1
ATE260104T1 AT98201404T AT98201404T ATE260104T1 AT E260104 T1 ATE260104 T1 AT E260104T1 AT 98201404 T AT98201404 T AT 98201404T AT 98201404 T AT98201404 T AT 98201404T AT E260104 T1 ATE260104 T1 AT E260104T1
Authority
AT
Austria
Prior art keywords
glycolization
inhibition
advanced
end products
chem
Prior art date
Application number
AT98201404T
Other languages
English (en)
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE260104T1 publication Critical patent/ATE260104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98201404T 1993-12-21 1994-12-19 Hemmung der endprodukte fortgeschrittener glykolisierung ATE260104T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17060693A 1993-12-21 1993-12-21

Publications (1)

Publication Number Publication Date
ATE260104T1 true ATE260104T1 (de) 2004-03-15

Family

ID=22620568

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98201404T ATE260104T1 (de) 1993-12-21 1994-12-19 Hemmung der endprodukte fortgeschrittener glykolisierung
AT94309461T ATE207749T1 (de) 1993-12-21 1994-12-19 Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung von atherosklerose und ischämischer herzerkrankungen
AT01200197T ATE254459T1 (de) 1993-12-21 1994-12-19 Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur hemmung der ldl oxidation und der atherosclerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT94309461T ATE207749T1 (de) 1993-12-21 1994-12-19 Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung von atherosklerose und ischämischer herzerkrankungen
AT01200197T ATE254459T1 (de) 1993-12-21 1994-12-19 Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur hemmung der ldl oxidation und der atherosclerose

Country Status (20)

Country Link
EP (3) EP1095654B1 (de)
JP (1) JPH07196498A (de)
KR (1) KR950016722A (de)
CN (1) CN1095663C (de)
AT (3) ATE260104T1 (de)
AU (1) AU698389B2 (de)
CA (1) CA2138508A1 (de)
CZ (1) CZ286365B6 (de)
DE (3) DE69433578T2 (de)
DK (2) DK0664121T3 (de)
ES (3) ES2163425T3 (de)
HU (1) HUT71476A (de)
IL (1) IL112034A (de)
NO (1) NO313083B1 (de)
NZ (1) NZ270162A (de)
PT (3) PT1095654E (de)
RU (1) RU2127592C1 (de)
TW (1) TW427902B (de)
UA (1) UA39941C2 (de)
ZA (1) ZA9410091B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
DE69622472T2 (de) * 1995-06-07 2003-02-06 Eli Lilly And Co., Indianapolis Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP0801066A1 (de) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterozyklisch substituierte Benzothiophene und pharmazeutische Zusammensetzungen
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
WO2000010606A1 (fr) 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux
RU2464794C1 (ru) * 2011-10-25 2012-10-27 Канапья Табылдыевич Шагиев Состав для производства кисломолочного продукта "курт"
CN103768601A (zh) * 2012-10-22 2014-05-07 中国科学院上海生命科学研究院 抑制micro-RNA155用于预防和治疗动脉粥样硬化的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
ES2163425T3 (es) 2002-02-01
RU94045270A (ru) 1996-10-20
DK0664121T3 (da) 2001-12-03
NO944913D0 (no) 1994-12-19
CN1095663C (zh) 2002-12-11
ES2210089T3 (es) 2004-07-01
EP1095654A3 (de) 2001-06-13
EP0963756B1 (de) 2004-02-25
RU2127592C1 (ru) 1999-03-20
DE69433348T2 (de) 2004-08-26
EP0963756A2 (de) 1999-12-15
JPH07196498A (ja) 1995-08-01
DE69433578T2 (de) 2004-12-16
CN1108090A (zh) 1995-09-13
PT963756E (pt) 2004-06-30
ATE254459T1 (de) 2003-12-15
ZA9410091B (en) 1996-06-19
AU698389B2 (en) 1998-10-29
CA2138508A1 (en) 1995-06-22
CZ320494A3 (en) 1995-09-13
NZ270162A (en) 1997-06-24
PT1095654E (pt) 2004-04-30
DE69428882D1 (de) 2001-12-06
EP1095654A2 (de) 2001-05-02
IL112034A (en) 1999-03-12
EP0664121B1 (de) 2001-10-31
DE69433348D1 (de) 2003-12-24
EP0664121A1 (de) 1995-07-26
EP0963756A3 (de) 1999-12-22
DE69433578D1 (de) 2004-04-01
CZ286365B6 (cs) 2000-03-15
ATE207749T1 (de) 2001-11-15
IL112034A0 (en) 1995-03-15
KR950016722A (ko) 1995-07-20
NO313083B1 (no) 2002-08-12
TW427902B (en) 2001-04-01
HUT71476A (en) 1995-11-28
AU8156394A (en) 1995-06-29
DE69428882T2 (de) 2002-04-25
DK1095654T3 (da) 2004-03-15
ES2215270T3 (es) 2004-10-01
NO944913L (no) 1995-06-22
HU9403660D0 (en) 1995-02-28
EP1095654B1 (de) 2003-11-19
UA39941C2 (uk) 2001-07-16
PT664121E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE260104T1 (de) Hemmung der endprodukte fortgeschrittener glykolisierung
GR3023537T3 (en) Inhibition of thrombin.
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
ATE216582T1 (de) Hemmung uteriner fibrose
GR3023378T3 (en) Inhibition of seborrhea and acne.
ES2154669T3 (es) Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para la inhibicion de la degradacion del cartilago.
AU7578694A (en) Methods for treating resistant neoplasms
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0963756

Country of ref document: EP

REN Ceased due to non-payment of the annual fee